# Quantum Cyber N.V.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Quantum Cyber N.V.).

## Overview

Quantum Cyber N.V. is a U.S.-based life sciences company that has developed in-vitro diagnostic tests for early cancer detection, including colorectal and pancreatic screening products. The company has also held intellectual property and related assets tied to these diagnostic programs and has operated through subsidiaries and commercialization partners in Europe.

## Products & services

• ColoAlert colorectal cancer screening test
• Next Gen colorectal cancer IP and related assets
• Blood-based pancreatic cancer detection product candidate
• Stool-based pancreatic cancer detection product candidate
• Diagnostic consumables and customer-located instrumentation

- **Colorectal cancer screening** (55%) — Stool-based and related colorectal cancer detection products and assets.
- **Pancreatic cancer screening** (25%) — Blood-based and stool-based pancreatic cancer detection development programs.
- **Intellectual property and asset sales** (15%) — Sales of diagnostic IP, product assets, and related equipment or lease obligations.
- **Consumables and instrumentation** (5%) — Consumables and customer-located instruments used with diagnostic testing.

- ColoAlert colorectal cancer screening test
- Next Gen colorectal cancer intellectual property
- Blood-based pancreatic cancer detection candidate
- Stool-based pancreatic cancer detection candidate
- Diagnostic consumables and instrumentation

## Customers

The company’s customers have included laboratory partners, diagnostic distributors, and other commercial counterparties involved in cancer screening workflows. Its products are designed for use in clinical testing settings where early detection, sample processing, and test commercialization matter. It also sells or transfers intellectual property and related assets to third-party buyers when monetizing product lines or programs.

- **Laboratory partners** (primary) — Buy ColoAlert and related consumables for use in screening workflows and last-time purchases.
- **Diagnostic commercialization partners** (primary) — Distribute or support cancer screening products in European markets.
- **IP and asset buyers** (secondary) — Acquire product lines, intellectual property, and related equipment for strategic use.
- **Clinical testing end users** (secondary) — Use the company’s diagnostic products through partner channels for early cancer detection.
- **Future strategic collaborators** (emerging) — Potential partners for development and commercialization of pancreatic screening programs.

- Laboratory partners purchasing ColoAlert for screening workflows
- Diagnostic commercialization partners in Europe
- Third-party buyers of diagnostic IP and product assets
- Clinical testing organizations needing consumables and instruments
- Potential future partners for pancreatic cancer detection

## Geography

The company has historically operated in Europe through its German subsidiary and marketed ColoAlert in European markets. Its development and commercialization efforts have also been oriented toward the United States and Europe, while recent asset sales included a buyer incorporated in Italy. Geography matters because the business depends on cross-border regulatory, partner, and commercialization pathways.

- European markets were the main commercial area for ColoAlert
- Germany housed the operating subsidiary and development activity
- United States was a target market for future colorectal launch
- Italy appeared as the buyer location in a 2026 IP sale
- Cross-border operations increase regulatory and partner complexity

## Strategy

The company’s strategy has centered on narrowing its focus to pancreatic cancer screening while monetizing legacy colorectal assets. It has also signaled an expanded emphasis on post-quantum cybersecurity alongside continued pursuit of blood-based pancreatic cancer detection, making the business a hybrid of life sciences and adjacent technology ambitions. Capital raising and strategic partnerships remain important to fund development and commercialization efforts.

- **Advance pancreatic cancer screening commercialization** (medium-term) — This is the remaining core life sciences program after the colorectal exit.
- **Monetize non-core diagnostic assets** (short-term) — Asset sales can convert legacy IP into cash and simplify the portfolio.
- **Secure external financing** (short-term) — Development-stage diagnostics require ongoing capital for R&D and operations.

- Focus on pancreatic cancer screening development
- Monetize legacy colorectal assets through sales
- Pursue strategic partnerships and collaboration funding
- Maintain access to equity and debt financing
- Expand into post-quantum cybersecurity as a new focus

## Risks

The company faces going-concern and financing risk because it has recurring losses and depends on external capital to fund development and operations. It also faces execution risk in diagnostic development, regulatory approval, and commercialization, especially as it transitions away from its legacy colorectal business. Additional risk comes from asset divestitures, partner dependence, and the uncertainty of building a new strategic identity around pancreatic screening and cybersecurity.

- **Going-concern and liquidity dependence** [critical] — The company has recurring losses and needs external financing to continue operations.
- **Commercialization and regulatory risk** [high] — Diagnostic products require validation, approvals, and market adoption before scaling.
- **Portfolio transition risk** [high] — Exiting colorectal cancer screening can reduce near-term revenue and operational continuity.
- **Partner concentration and asset monetization risk** [medium] — Revenue and cash generation depend on a limited set of lab partners and buyers.

- Going-concern risk if financing is not obtained
- Dependence on equity and debt markets for funding
- Regulatory and commercialization risk in diagnostics
- Execution risk from shifting away from colorectal products
- Partner and asset-sale dependence for monetization

## Accounting

Revenue recognition is important because the company’s diagnostic sales can include product shipments, last-time buys, and asset transactions that may be recognized at different points in time. Investors should also watch discontinued operations accounting, impairment charges, and stock-based compensation, all of which can materially affect reported results during a portfolio transition. Lease obligations, asset sales, and valuation judgments around intangible assets are also relevant because the business has relied on IP-heavy programs and restructuring-related transactions.

- **Revenue recognition for diagnostic product sales** — Reported revenue and gross margin
- **Discontinued operations** — Operating income and revenue comparability
- **Impairment of fixed and intangible assets** — Operating expenses and asset values
- **Stock-based compensation** — General and administrative expense

- Revenue timing for diagnostic sales and last-time buys
- Discontinued operations presentation for exited colorectal business
- Impairment of fixed assets and other long-lived assets
- Stock-based compensation in general and administrative expense
- Lease obligations transferred in asset sales

---

*Last updated: 2026-06-16T23:06:59.875977+00:00*